Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 14/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 13/20 | 0.60 |
| ▸ | OPRD1 | P41143 | 13/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 13/20 | 0.60 |
| ▸ | DRD4 | P21917 | 3/20 | 0.53 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 4/20 | 0.52 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.52 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.52 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.52 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.52 |
| ▸ | DRD2 | P14416 | 3/20 | 0.51 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.51 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | HRH1 | P35367 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4319712 | 0.88 | OPRL1 (0.66) | OPRL1OPRM1OPRD1OPRK1DRD4 | |
| SCHEMBL4322410 | 0.88 | OPRL1 (0.62) | OPRL1OPRM1OPRD1OPRK1DRD4 | |
| SCHEMBL8258243 | 0.85 | OPRL1 (0.62) | OPRL1OPRM1OPRD1OPRK1DRD4 | |
| SCHEMBL4339359 | 0.85 | OPRL1 (0.39) | OPRL1OPRM1OPRD1OPRK1DRD4 | |
| SCHEMBL4332755 | 0.83 | OPRL1 (0.56) | OPRL1OPRM1OPRD1OPRK1DRD4 | |
| SCHEMBL4327183 | 0.82 | DRD2 (0.52) | OPRL1OPRM1OPRD1OPRK1DRD4 | |
| SCHEMBL4331579 | 0.81 | OPRL1 (0.64) | OPRL1OPRM1OPRD1OPRK1DRD4 | |
| SCHEMBL9912156 | 0.79 | OPRL1 (0.74) | OPRL1OPRM1OPRD1OPRK1DRD4 | |
| SCHEMBL4326986 | 0.79 | OPRL1 (0.61) | OPRL1OPRM1OPRD1OPRK1DRD4 | |
| SCHEMBL4331159 | 0.78 | OPRL1 (0.62) | OPRL1OPRM1OPRD1OPRK1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| EP-1833800-A1 | PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006071730-A1 | PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ASTRAZENECA AB (SE) | 2006-07-06 | — | — | WO | disclosed |
| WO-2006071730-A1 | PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ASTRAZENECA AB (SE) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | GRIN1, GRM1, GRIN3A | OPRL1 96/4885OPRM1 264/4885OPRD1 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.